Sept. 2 - Top lawmaker targets AbbVie on drug pricing | Nestle's bid to boost a struggling peanut allergy drug

Nestlé buys the rest of Aimmune, aiming to boost a struggling peanut allergy treatment; Healthcare workers likely to be first in line for coronavirus vaccination; BioMarin's hemophilia gene therapy could have warranted a record price tag, ICER finds View online | Signup | Forward

Marketing weekly Sept.​ 2,​ 2020 | This week's marketing news and insights for biopharma leaders   BROUGHT TO YOU BY — TrialCard Virtual Engagements for HCP Access TrialCard's virtual engagement program serves as a complement to a pharma brand's field sales force. Download the e-book and register for this webcast.   House committee to subpoena AbbVie over drug pricing Democratic lawmakers have been unhappy with AbbVie's response to an ongoing drug pricing probe, and are now demanding the drugmaker turn over more information. Nestlé buys the rest of Aimmune, aiming to boost a struggling peanut allergy treatment The Swiss firm will take over the launch of Aimmune's Palforzia, sales of which have disappointed since its approval in January.   Healthcare workers likely to be first in line for coronavirus vaccination Initial vaccine supplies will be limited. Advisory groups, most recently the National Academies, are developing plans for who should get access first. Sponsored Content by BioPharma Dive Brand Studio Changes driving oncology market growth Oncology is pharma’s largest sector, with nearly $150 billion spending on medicines in 2018. Explore the progress in precision oncology development, and the benefits of CDMO partners in this trend report. BioMarin's hemophilia gene therapy could have warranted a record price tag, ICER finds A draft report from the drug pricing watchdog concluded that, under the right conditions, Roctavian may be cost-effective at a price of $2.5 million. Read more news From Our Library Infographic The Biologic's Path to Clinic By Brand Studio View all resources What We're Reading PR Week Fors Marsh Group wins $250m-plus HHS contract for campaign to 'defeat despair' MM&M Marketers step up use of non-personal promotion during pandemic POLITICO FDA shake-up continues as another comms official removed from top role Suggest a story we should read Dive Into a Topic Pharma Biotech FDA Clinical Trials Deals Drug Pricing Gene Therapy Share BioPharma Dive: Marketing Weekly with others and get rewarded. You've referred 1 readers. Here's your link to share: https://www.biopharmadive.com/signup/insiders/?signup_referred_by=5ef5e39c0913eb2a7835e73c

More Than A Newsletter Related Publications Healthcare Dive | MedTech Dive Connect With Us Twitter | Facebook | LinkedIn Editorial Contact an editor | Meet the team Advertising Contact our team About BioPharma Dive BioPharma Dive provides in-depth journalism and insight into the most impactful news and trends shaping biotech and pharma. The newsletter and website cover topics ranging from clinical readouts to FDA approvals, gene therapy to drug pricing and M&A to research partnerships. BioPharma Dive is a leading industry publication operated by Industry Dive. Our business journalists spark ideas and shape agendas for 10+ million decision makers in the most competitive industries. Sign up for the newsletter This email is optimized for display on mobile phones. BioPharma Dive: Marketing Weekly is a product of Industry Dive, Inc.. 1575​ Eye St NW, 4th Floor, Washington,​ DC 20005. We value your privacy. We won't share your email address with anyone else without your permission. This message was sent to majed2aboshddad.majed@blogger.com. You can unsubscribe anytime. See our full privacy policy.

Sign up | Manage subscription | Advertise with us | Submit story tip